Eli Lilly (LLY) and Amgen (AMGN) filed a complaint Friday against the US Department of Health and Human Services, alleging that the agency unlawfully certified and recertified clinics that treat sexually transmitted diseases to participate in a federal drug discount program.

The plaintiffs said in the lawsuit that the court "should set aside the agency's unlawful certifications and recertifications of these ineligible entities and enjoin the agency from certifying or recertifying these entities in the future."

The Department of Health and Human Services did not immediately reply to a request for comment from MT Newswires.

Price: 791.19, Change: +23.43, Percent Change: +3.05